Tyr142
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr142  -  CD3Z (mouse)

Site Information
GKGHDGLyQGLsTAT   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448932

In vivo Characterization
Methods used to characterize site in vivo:
flow cytometry ( 2 , 4 ) , immunoassay ( 1 ) , immunoprecipitation ( 5 ) , mass spectrometry ( 6 , 7 , 8 , 9 ) , mutation of modification site ( 5 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 ) , western blotting ( 2 , 3 , 5 )
Disease tissue studied:
leukemia ( 1 , 2 ) , T cell leukemia ( 1 , 2 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 2 ) , brain ( 9 ) , CD4+ (T lymphocyte) ( 3 ) , HEK293T (epithelial) ( 5 ) , Jurkat (T lymphocyte) ( 1 , 2 ) , lymphocyte ( 1 ) , skin ( 4 ) , spleen ( 8 ) , T lymphocyte-lymph node ( 6 ) , T lymphocyte-spleen ( 3 ) , thymocyte ( 2 ) , thymus ( 7 )

Upstream Regulation
Regulatory protein:
CDK6 (human) ( 1 )
Putative in vivo kinases:
Lck (human) ( 2 , 4 , 5 )
Kinases, in vitro:
Lck (human) ( 5 )
Putative upstream phosphatases:
PTP1B (human) ( 1 ) , PTPN2 (human) ( 1 )
Treatments:
palbociclib ( 1 ) , PP2 ( 1 , 4 ) , PP3 ( 4 ) , PTP1B_inhibitor_compound_II ( 1 ) , siRNA ( 1 )

Downstream Regulation
Effects of modification on biological processes:
apoptosis, induced ( 1 ) , carcinogenesis, inhibited ( 1 ) , signaling pathway regulation ( 1 , 3 )

References 

1

Gao X, et al. (2023) Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance. Cell Rep 42, 112314
37000627   Curated Info

2

Horkova V, et al. (2023) Unique roles of co-receptor-bound LCK in helper and cytotoxic T cells. Nat Immunol 24, 174-185
36564464   Curated Info

3

Zinzow-Kramer WM, Weiss A, Au-Yeung BB (2019) Adaptation by naïve CD4 T cells to self-antigen-dependent TCR signaling induces functional heterogeneity and tolerance. Proc Natl Acad Sci U S A 116, 15160-15169
31285342   Curated Info

4

Chodaczek G, Papanna V, Zal MA, Zal T (2012) Body-barrier surveillance by epidermal γδ TCRs. Nat Immunol 13, 272-82
22327568   Curated Info

5

Gelkop S, et al. (2012) Development of unique antibodies directed against each of the six different phosphotyrosine residues within the T cell receptor CD3ζ chain. J Immunol Methods 375, 129-37
22020291   Curated Info

6

Iwai LK, Benoist C, Mathis D, White FM (2010) Quantitative phosphoproteomic analysis of T cell receptor signaling in diabetes prone and resistant mice. J Proteome Res 9, 3135-45
20438120   Curated Info

7

Guo A (2009) CST Curation Set: 7710; Year: 2009; Biosample/Treatment: tissue, thymus/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

8

Guo A (2009) CST Curation Set: 7708; Year: 2009; Biosample/Treatment: tissue, spleen/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

9

Zhou J (2009) CST Curation Set: 7383; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST]
Curated Info